AMLN Amylin Pharmaceuticals, Inc. (MM)

Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for Public Offering of Common Stock SAN DIEGO, Jan. 18 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that it has filed a preliminary prospectus supplement to its shelf registration statement with the Securities and Exchange Commission relating to a proposed underwritten public offering of 6.5 million shares of its common stock. To the extent that the underwriters sell more than 6.5 million shares, the company also will grant an over- allotment option to the underwriters for the purchase of up to an additional 975,000 shares of common stock. All of the shares are being sold by Amylin Pharmaceuticals. Morgan Stanley & Co. Incorporated is acting as the sole book running and joint lead manager for the offering announced today. Goldman, Sachs & Co. is acting as joint lead manager of the offering. Co-managers for the offering are Banc of America Securities LLC, J.P. Morgan Securities Inc., and Wachovia Capital Markets, LLC. These securities may not be sold nor may offers to buy be accepted prior to the time that the prospectus supplement is final. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The common stock is being offered in connection with a distribution by the issuer and represents new financing. Amylin Pharmaceuticals is committed to improving the lives of people with diabetes and other metabolic diseases through the discovery, development and commercialization of innovative, cost-effective medicines. Copies of the preliminary prospectus supplement may be obtained from the Prospectus Departments of Morgan Stanley & Co. Incorporated (1585 Broadway, New York, New York 10036, phone 212-761-6775, fax 212-761-0211), Goldman, Sachs & Co. (Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, phone 212-902-1171, fax 212-902-9316), Banc of America Securities LLC (9 West 57th Street, New York, NY 10019, phone 888-583-8900), J.P. Morgan Securities Inc. (1 Chase Manhattan Plaza, Floor 5B, New York, New York 10081, phone 212-552-5164) and Wachovia Capital Markets, LLC (7 St. Paul Street, Baltimore, Maryland 21202, phone 443-263-6400, fax 443-263-6894). DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Mark G. Foletta, Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site: http://www.amylin.com/

Copyright